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There is now some robust data on the role
of pharmacotherapy, in the form of drug
substitution, in the management of opiate
dependence. The efficacy of methadone
maintenance treatment has been well
reported and there is considerable interest
now in exploring the diversification in the
use of other opiate agonists in the substi-
tution treatment of opiate dependence.
There is extensive interest in a multidi-
mensional approach to the measure of
treatment outcome in drug dependence.
Such measures look at the impact on pat-
terns of drug and alcohol use, risk taking
behaviour such as injecting and sharing,
impact on mental and physical well being
and impact on social well being including
impact on criminal behaviour.
Numerous reviews of methadone main-
tenance (Farrell et al 1994, Ward, Mattick
and Hall 1997 and Marsch 1998) indicate
a consistent finding of impact on reducing
opiate consumption, reducing injecting
risk behaviour and reducing criminality, in
major studies. The majority of studies
report a 60% reduction in heroin con-
sumption and in criminal behaviour and a
commensurate improvement in reports of
health and social well being.
A recent National UK study of the
impact of treatment, in an observational
study reports that, at two years of commu-
nity treatment with a mixture of
methadone and other psychosocial inter-
ventions, 20% had achieved total absti-
nence, indicating that for a significant
minority methadone treatment does not
imply indefinite treatment. However
there was also a major cohort who required
longer term methadone maintenance. The
cost effectiveness evaluation of this inter-
vention is estimated to range from a saving
of between £3 and £7 pound for every £
spent on treatment.
In many European countries there is a
clear policy thrust to increase the level of
provision of methadone maintenance
treatment in primary care settings. The
limited data available indicates that out-
comes in primary care settings match those
of more specialist settings (Task Force
1995).
The issue of the role of the other aspects
of a treatment programme requires further
consideration, in particular the role of
supervised versus unsupervised medication
and the role of adjunctive psychosocial
interventions. There is major variation in
the range and provision of such services
(Farrell et al 1996). There is also major
variation in programme effectiveness (Ball
and Ross 1991). Me Lellan et al indicate
the efficacy and cost effectiveness of mod-
erate levels of psychosocial interventions in
conjunction with methadone maintenance
but there is a need for further evaluation of
these interventions. Recent work by
McLellan (1999) and colleagues indicates
in a randomised study that the introduc-
tion of case managers into drug and alco-
hol treatment services can significantly
improve treatment outcomes.
THE DEVELOPMENT OF NEW CLINICAL
PROCEDURES
Oral methadone is likely to remain the
most commonly used substitute, but alter-
native long acting mu opioid agonists
(Jaffe and Martin 1990) will also become
available. Since 1993 levo-alpha-acetyl-
methadol (LAAM) has been approved for
use in American clinics. The effects of
LAAM are characterised by delayed onset
and longer duration of action than
methadone. Dosing in the range 70-
lOOmg appears capable of suppressing
withdrawal symptoms for 48-72 hours,
thereby permitting three-times weekly
administration (Ling et al. 1994).
Research on the feasibility and effective-
ness of LAAM maintenance in the British
context would now be beneficial. It is like-
ly that this drug will need to be dispensed
in an oral formulation under direct super-
vision. Given the delayed onset of action
(some three to six hours following intra-
venous administration), LAAM may lead
to a serious risk of overdose if take-home
doses are provided.
There is also international interest and
some practice (particularly in France) in
using buprenorphine (temgesic), a partial
mu opioid agonist, for substitution
(Johnson et al. 1995). Buprenorphine is
not orally active and tablets must be taken
sublingually. In Britain, the history of
buprenorphine has been marred by harm-
ful illicit use associated with tablet injec-
tion (particularly in Scotland). Research
and development initiatives will need to
assess supervised administration in order
to minimise the risk of diversion if this
agent is to be used successfully.
There is also continuing interest in the
prescribing of injectable diamorphine itself
as a small element within a methadone
prescription regime or, in some cases, as
the sole substitute. Internationally, a con-
trolled trial of supervised diamorphine
administration in maintenance treatment
is reaching completion in Switzerland
(Uchtenhagen et al. 1996, Farrell and Hall
1998). A study has been commenced in
the Netherlands and other countries are
debating embarking on projects imple-
menting heroin prescribing. Further
research to profile the characteristics of
patients for whom diamorphine substitu-
tion is a possible management strategy
would now be of value. However no good
comparative efficacy studies have been
conducted and preliminary data does not
support there being a major role for
injectable prescribing, particularly in situa-
tions where treatment demand exceeds
treatment provision (Farrell and Hall
1998)
IN CONCLUSION
There is a growing acceptance of the
value and efficacy of opiate substitution
treatment using a range of opiate agonist
substitutes. There is a need for further
exploration of the impact of other treat-
ment processes and the amount of psy-
chosocial intervention required to achieve
the most cost-effective intervention.
The current challenge is to fashion
treatment programmes in a manner that
provides the most effective gains in both
health behaviour and reduced criminal
offending behaviour and is delivered in a
fashion that ensures rapid and equitable
access. Case managers or other co-ordina-
tor approaches are required to ensure that
individuals with complex physical, psy-
chological and social problems receive
appropriate care.
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